Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)

Rhea-AI Summary

Pyxis Oncology (PYXS) will host a live webcast on September 9, 2026 at 7:30 a.m. ET to present updated clinical data from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC).

The event will review scientific rationale for MICVO, implications of the evolving R/M HNSCC treatment landscape, detailed analyses of patients treated at 5.4 mg/kg every three weeks, updated efficacy and safety from the expansion trial, and next clinical development steps. The webcast will feature Alan L. Ho, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center and Pyxis management, with a replay available on the company’s investor website.

Argus Sep 9 session 38 alerts

-13.11% close to close 551.8x rel. volume Open Argus

Details

Market move: PYXS -13.11% in the Sep 9 session. Phase 1 data webcast

+6.8% Peak Tracked

-31.9% Trough Tracked

$366.16M Mkt Cap at Peak Alert

On Sep 9, the first trading day after this news, PYXS closed 13.11% below the previous close. Argus tracked a peak move of +6.8% during that session. Argus tracked a trough of -31.9% from its starting point during tracking. Our momentum scanner recorded 38 alerts for this stock that day. Relative volume reached 551.8x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 9 session.

Key Figures

Study phase: Phase 1 Dose level: 5.4 mg/kg Webcast date: September 9, 2026 +1 more

Study phase

Phase 1

Ongoing MICVO monotherapy study

Dose level

5.4 mg/kg

Patients treated intravenously once every three weeks

Webcast date

September 9, 2026

Presentation of updated clinical data

Webcast time

7:30 a.m. ET

Live presentation

Key Terms

antibody-drug conjugate, immunogenic cell death, fast track designation

3 terms

antibody-drug conjugate medical

"MICVO, is a first-in-concept antibody-drug conjugate (ADC)"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

immunogenic cell death medical

"bystander effect and immunogenic cell death"

Immunogenic cell death is a form of cell death that not only kills diseased cells (such as cancer cells) but also releases signals that alert and activate the immune system to recognize and attack remaining disease. For investors, therapies that trigger this response can increase the chance of durable, long-lasting treatment effects—like sounding an alarm that recruits security guards—making such drugs potentially more valuable and differentiable in the market.

fast track designation regulatory

"MICVO received Fast Track Designation from the U.S. Food and Drug"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Event to be webcast live on September 9, 2026 at 7:30 a.m. ET

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

The presentation will include the scientific rationale for Pyxis Oncology’s novel ADC, MICVO; implications of the evolving treatment landscape in R/M HNSCC; detailed analyses of patients treated at 5.4 mg/kg intravenously once every three weeks with a dose equivalent to or below a dose cap; updated efficacy and safety results from the expansion trial; and next steps in clinical development.

The event will feature Alan L. Ho, M.D., Ph.D., Chief, Head and Neck Oncology Service and Attending Medical Oncologist at Memorial Sloan Kettering Cancer Center, together with members of Pyxis Oncology’s management team.

To participate in the live event, please register using this link. An archived webcast will be available following the event on the Company's website at, https://ir.pyxisoncology.com.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.

Pyxis Oncology Contact
IR@pyxisoncology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors and other interested parties access the Pyxis Oncology webcast?

To participate in the live event, attendees are asked to register using the provided online link. An archived webcast of the presentation will be available after the event on Pyxis Oncology’s website at https://ir.pyxisoncology.com.

What is micvotabart pelidotin (MICVO) and what is its current clinical development status?

MICVO is described as a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin (EDB+FN), a structural component of the tumor extracellular matrix that is selectively overexpressed in many solid tumors and largely absent from normal adult tissues. MICVO is designed to act through direct cancer cell killing, a bystander effect, and immunogenic cell death. It is being evaluated as monotherapy in a Phase 1 study in recurrent/metastatic head and neck squamous cell carcinoma and in combination with KEYTRUDA in a Phase 1/2 study in R/M HNSCC and other solid tumors, and has received FDA Fast Track Designation for certain adult patients with R/M HNSCC whose disease has progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy.